Personalized medicine is about changing the medical paradigm. It promises to replace trial-and-error medicine with a more targeted get-it-right-the-first-time approach.”

Edward Abrahams,  Executive Director,
Personalized Medicine Coalition
in Washington, D.C.

CTI’s SynRx™ Laboratory Technology Discovers Patentable, Synergistic Combinations of FDA-approved Drugs with Unparalleled Efficacy

The platform technology SynRx™ predicts clinical outcomes in patients for individual and combination drugs and was used to discover CT301.
SynRx™ will also be used to develop a companion diagnostic for CT301 and a pipeline of additional drug combinations.
  • We believe SynRx™ is the only laboratory technology capable of discovering unique drug combinations that are safe and effective due to synergy.
  • We focus on repurposing existing generic cancer drugs where we find synergy because safety profiles are already known.
  • Our platform will disrupt current cancer treatment paradigms at unparalleled speed and savings.
  • The SynRx™ technology has been validated by the discovery of CT301.
  • We have discovered a second product with SynRx™ that we are moving to early clinical studies.
  • Newly discovered drug combinations will quickly move to Phase II Clinical Trials.
  • Our goal is synergistic activity leading to durable complete remissions with limited side effects.